LH · Insider Trading
Labcorp Holdings Inc.
Every open-market purchase and sale reported by LH officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Form 4 Filings
50
most recent
Open-Market Buys
0
code P
Sales
10
code S
Reporting Insiders
24
current holders
LH — Recent Form 4 Transactions (latest 2026-09-03)
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-03 | Brian J Caveney | EVP, Pres of BLS, CMO & CSO | A | +3,000 deriv. | — |
| 2026-09-03 | Jonathan C Meltzer | EVP, COO | A | +900 deriv. | — |
| 2026-09-03 | Akinbolade Oyegunwa | EVP, CIO & CTO | A | +750 deriv. | — |
| 2026-09-03 | Bryan T Vaughn | EVP and President, Diagnostics | A | +1,500 deriv. | — |
| 2026-08-18 | Kerrii B Anderson | Director | Sell | −3,000 | −$954.06K |
| 2026-08-12 | Adam H Schechter | President & CEO | Sell | −4,669 | −$1.50M |
| 2026-08-06 | Amy B. Summy | EVP, Chief Marketing Officer | Sell | −924 | −$283.43K |
| 2026-08-06 | Amy B. Summy | EVP, Chief Marketing Officer | Sell | −924 | −$283.43K |
| 2026-08-05 | Peter J Wilkinson | SVP, Chief Accounting Officer | MIXED | −82 | −$159.13K |
| 2026-07-06 | Bryan T Vaughn | EVP and President, Diagnostics | MIXED | — | −$93.37K |
| 2026-07-06 | Kathryn W Kyle | EVP, Chief Legal Officer | MIXED | +91 | −$47.05K |
| 2026-06-10 | Kathryn W Kyle | EVP, Chief Legal Officer | Sell | −762 | −$201.08K |
| 2026-05-13 | Adam H Schechter | President & CEO | Sell | −5,903 | −$1.50M |
| 2026-03-30 | Megan D. Bailey | EVP, Pres, Central Labs & Intl | MIXED | +703 | −$129.09K |
| 2026-03-30 | Kathryn W Kyle | EVP, Chief Legal Officer | MIXED | +1,133 | −$121.04K |
| 2026-03-30 | Jonathan C Meltzer | EVP, Operations | MIXED | +838 | −$414.87K |
| 2026-03-30 | Akinbolade Oyegunwa | EVP, CIO & CTO | MIXED | +958 | −$102.52K |
| 2026-03-30 | Amy B. Summy | EVP, Chief Marketing Officer | MIXED | +2,158 | −$492.75K |
| 2026-03-30 | Vaart Sandra D van der | EVP, Corporate Affairs | MIXED | +3,660 | −$730.53K |
| 2026-03-30 | Bryan T Vaughn | EVP, Diagnostics | MIXED | +1,133 | −$121.04K |
| 2026-03-30 | Peter J Wilkinson | SVP, Chief Accounting Officer | MIXED | — | −$638.72K |
| 2026-03-30 | Brian J Caveney | EVP, Pres of ED, CMO & CSO | MIXED | +6,385 | −$1.32M |
| 2026-03-30 | Mark S Schroeder | EVP, Pres Diagnostics & COO | MIXED | +6,204 | −$1.63M |
| 2026-03-30 | Anita Z Graham | EVP, CHRO | MIXED | +3,725 | −$772.67K |
| 2026-03-30 | Adam H Schechter | President & CEO | MIXED | +32,364 | −$7.01M |
| 2026-03-05 | Adam H Schechter | President & CEO | Sell | −8,705 | −$2.44M |
| 2026-03-03 | Vaart Sandra D van der | EVP, Corporate Affairs | Sell | −547 | −$156.00K |
| 2026-02-26 | Brian J Caveney | EVP, Pres of ED, CMO & CSO | Sell | −1,500 | −$429.46K |
| 2026-02-23 | Peter J Wilkinson | SVP, Chief Accounting Officer | Sell | −666 | −$185.11K |
| 2026-02-13 | Kerrii B Anderson | Director | M | +897 | — |
| 2026-02-13 | Jeffrey A. Davis | Director | M | +897 | — |
| 2026-02-13 | Kirsten Marie Kliphouse | Director | M | +897 | — |
| 2026-02-13 | Garheng Kong | Director | M | +897 | — |
| 2026-02-13 | Peter M Neupert | Director | M | +897 | — |
| 2026-02-13 | Richelle P Parham | Director | M | +897 | — |
| 2026-02-13 | Kathryn E Wengel | Director | M | +897 | — |
| 2026-02-13 | Paul Rothman | Director | M | +897 | — |
| 2026-02-13 | Megan D. Bailey | EVP, Pres, Central Labs & Intl | MIXED | +265 | −$40.00K |
| 2026-02-13 | Brian J Caveney | EVP, Pres of ED, CMO & CSO | MIXED | +529 | −$61.17K |
| 2026-02-13 | Anita Z Graham | EVP, CHRO | MIXED | +247 | −$31.60K |
| 2026-02-13 | Kathryn W Kyle | EVP, Chief Legal Officer | MIXED | +154 | −$17.97K |
| 2026-02-13 | Jonathan C Meltzer | EVP, Operations | MIXED | +86 | −$45.56K |
| 2026-02-13 | Akinbolade Oyegunwa | EVP, CIO & CTO | MIXED | +162 | −$19.71K |
| 2026-02-13 | Adam H Schechter | President & CEO | MIXED | −3,138 | −$1.94M |
| 2026-02-13 | Mark S Schroeder | EVP, Pres Diagnostics & COO | MIXED | +547 | −$75.08K |
| 2026-02-13 | Vaart Sandra D van der | EVP, Corporate Affairs | MIXED | +277 | −$28.70K |
| 2026-02-13 | Bryan T Vaughn | EVP, Diagnostics | MIXED | +230 | −$26.96K |
| 2026-02-13 | Julia Aijun Wang | Chief Financial Officer, EVP | MIXED | +615 | −$71.02K |
| 2026-02-13 | Peter J Wilkinson | SVP, Chief Accounting Officer | MIXED | +490 | −$59.72K |
| 2026-02-13 | Amy B. Summy | EVP, Chief Marketing Officer | MIXED | +147 | −$24.06K |
LH — Current Insider Holders
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Adam H Schechter | President & CEO | 102,565 | $32.61M |
| Glenn A Eisenberg | Executive Vice President | 41,550 | $13.21M |
| Brian J Caveney | EVP, Pres of BLS, CMO & CSO | 35,368 | $11.25M |
| Lance Berberian | EVP, Special Advisor, Strategy | 20,005 | $6.36M |
| Mark S Schroeder | EVP, Pres Diagnostics & COO | 15,777 | $5.02M |
| Peter M Neupert | Director | 13,784 | $4.38M |
| Garheng Kong | Director | 13,739 | $4.37M |
| Vaart Sandra D van der | EVP, Corporate Affairs | 8,960 | $2.85M |
| Anita Z Graham | EVP, CHRO | 8,064 | $2.56M |
| Bryan T Vaughn | EVP and President, Diagnostics | 6,979 | $2.22M |
| Amy B. Summy | EVP, Chief Marketing Officer | 6,955 | $2.21M |
| Kerrii B Anderson | Director | 6,707 | $2.13M |
| Dwight Gary Gilliland | Director | 6,656 | $2.12M |
| Jeffrey A. Davis | Director | 5,460 | $1.74M |
| Akinbolade Oyegunwa | EVP, CIO & CTO | 5,064 | $1.61M |
| Megan D. Bailey | EVP, Pres, Central Labs & Intl | 4,851 | $1.54M |
| Jonathan C Meltzer | EVP, COO | 4,459 | $1.42M |
| Kathryn E Wengel | Director | 4,133 | $1.31M |
| Kathryn W Kyle | EVP, Chief Legal Officer | 3,904 | $1.24M |
| Richelle P Parham | Director | 3,366 | $1.07M |
| Kirsten Marie Kliphouse | Director | 3,160 | $1.00M |
| Paul Rothman | Director | 2,571 | $817.45K |
| Julia Aijun Wang | Chief Financial Officer, EVP | 2,062 | $655.69K |
| Peter J Wilkinson | SVP, Chief Accounting Officer | 1,770 | $562.84K |
LH Insider Trading FAQ
Who are the insiders at LH?
24 officers, directors and 10%+ beneficial owners currently report holdings in LH via SEC Form 4.
Are LH insiders buying or selling?
Across the 50 most recent Form 4 filings for LH, 0 were open-market purchases (code P) and 10 were sales (code S). Sales frequently reflect scheduled 10b5-1 plans or tax withholding rather than a view on the stock.
How current is LH insider data?
Form 4 must be filed within two business days of the transaction, so this is close to real time. The most recent LH filing is dated 2026-09-03.
How to read Form 4 activity
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the LH quote page; the site-wide leaderboard is on the insider transactions hub.
More on LH
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.